Russia's Rusnano, Epibiomed Join For $155 Million Nanotech-Drug Plant
This article was originally published in PharmAsia News
Executive Summary
Russian drug manufacturer Epidbiomed and Rusnano, a state-owned venture-capital company, are joining to build a $155 million production plant focused on nanotechnology-based products.